MIR12135: A Potential Drug Target and Biomarker (G113219462)
MIR12135: A Potential Drug Target and Biomarker
Molecular Intelligence (MI) has identified a potential drug target and biomarker for the study of neurodegenerative diseases, MIR12135. This gene has been shown to be involved in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases.
The discovery of MIR12135 as a potential drug target is significant because it has the potential to treat a wide range of neurodegenerative diseases. These conditions are debilitating and often progressive, and there is currently no cure. The development of new treatments is crucial for improving the quality of life for people with these conditions.
MIR12135 is also an attractive biomarker for neurodegenerative diseases. The protein produced by this gene has been shown to be involved in the development and progression of neurodegenerative diseases. By targeting MIR12135, researchers may be able to develop new diagnostic tools and treatments for these conditions.
The MIR12135 gene has also been shown to be involved in the development and progression of other neurological disorders, including cancer. This suggests that it may also be a potential drug target for cancer treatments.
In conclusion, the potential discovery of MIR12135 as a drug target and biomarker for neurodegenerative diseases is a promising development in the field of neuroscience. Further research is needed to understand the full potential of this gene and its role in the development and progression of these conditions.
Protein Name: MicroRNA 12135
The "MIR12135 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR12135 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR12136 | MIR122 | MIR1224 | MIR1225 | MIR1226 | MIR1227 | MIR1228 | MIR1229 | MIR1231 | MIR1233-1 | MIR1233-2 | MIR1234 | MIR1236 | MIR1237 | MIR1238 | MIR124-1 | MIR124-1HG | MIR124-2 | MIR124-2HG | MIR124-3 | MIR1243 | MIR1244-1 | MIR1244-2 | MIR1244-3 | MIR1245A | MIR1245B | MIR1246 | MIR1247 | MIR1248 | MIR1249 | MIR1250 | MIR1251 | MIR1252 | MIR1253 | MIR1254 | MIR1255A | MIR1255B1 | MIR1255B2 | MIR1256 | MIR1257 | MIR1258 | MIR125A | MIR125B1 | MIR125B2 | MIR126 | MIR1260A | MIR1260B | MIR1261 | MIR1262 | MIR1263 | MIR1264 | MIR1265 | MIR1266 | MIR1267 | MIR1268A | MIR1268B | MIR1269A | MIR1269B | MIR127 | MIR1270 | MIR1271 | MIR1272 | MIR1273A | MIR1273C | MIR1273H | MIR1275 | MIR1276 | MIR1277 | MIR1278 | MIR1279 | MIR128-1 | MIR128-2 | MIR1280 | MIR1281 | MIR1282 | MIR1283-1 | MIR1283-2 | MIR1284 | MIR1285-1 | MIR1285-2 | MIR1286 | MIR1287 | MIR1288 | MIR1289-1 | MIR1289-2 | MIR129-1 | MIR129-2 | MIR1290 | MIR1291 | MIR1292 | MIR1293 | MIR1294 | MIR1295A | MIR1295B | MIR1296 | MIR1297 | MIR1298 | MIR1299 | MIR1301 | MIR1302-1
